Invivo Therapeutics (NASDAQ:NVIV) released its quarterly earnings results on Monday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03, Bloomberg Earnings reports.
Invivo Therapeutics (NASDAQ NVIV) opened at $0.67 on Tuesday. Invivo Therapeutics has a 1 year low of $0.45 and a 1 year high of $4.40. The company has a debt-to-equity ratio of 0.04, a quick ratio of 5.06 and a current ratio of 5.06.
Invivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.